Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence
Abstract: Hepatitis E virus (HEV), which causes acute hepatitis, can progress to chronicity in immunosuppressed patients. Transfusion transmission has been reported, being asymptomatic carriers a virus reservoir and a potential threat to transfusion safety. In Argentina, HEV is not te...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2021
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/35087 |
| Aporte de: |
| id |
I10-R327-article-35087 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
HEV blood bank blood donors Córdoba HEV banco de sangre donantes de sangre Córdoba . |
| spellingShingle |
HEV blood bank blood donors Córdoba HEV banco de sangre donantes de sangre Córdoba . Di Cola, G Pisano , MB Blanco , S Fantilli, AC Martinez Wassaf , MG Carrizo , LH Ré , VE Gallego , SV Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| topic_facet |
HEV blood bank blood donors Córdoba HEV banco de sangre donantes de sangre Córdoba . |
| author |
Di Cola, G Pisano , MB Blanco , S Fantilli, AC Martinez Wassaf , MG Carrizo , LH Ré , VE Gallego , SV |
| author_facet |
Di Cola, G Pisano , MB Blanco , S Fantilli, AC Martinez Wassaf , MG Carrizo , LH Ré , VE Gallego , SV |
| author_sort |
Di Cola, G |
| title |
Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| title_short |
Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| title_full |
Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| title_fullStr |
Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| title_full_unstemmed |
Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence |
| title_sort |
study of the hepatitis e virus in blood donors from córdoba: serological and molecular prevalence |
| description |
Abstract:
Hepatitis E virus (HEV), which causes acute hepatitis, can progress to chronicity in immunosuppressed patients. Transfusion transmission has been reported, being asymptomatic carriers a virus reservoir and a potential threat to transfusion safety. In Argentina, HEV is not tested in blood banks and its control is a matter of debate. Our objective was to determine HEV serological and molecular prevalence in blood donors from Córdoba.
Five hundred and forty-seven plasma samples from blood donors (229 women, 318 men; median age: 35 years), obtained between February and May 2016 (n = 147), 2019 (n = 200), and 2020 (n = 200) were analyzed. IgG and IgM anti-HEV detection were performed by ELISA, and RNA detection was carried out by real-time RT-PCR and nested-PCR. Statistical analyzes were performed using R3.6.3 (statistical significance of p <0.05).
The global prevalence of anti-HEV IgG was 3.7% (19/547), being similar in all years: 2.05% in 2016 (3/147), 3.50% in 2019 (7/200) and 4.50% in 2020 (9/200) (p=0,47). A greater trend in HEV seroprevalence was observed in men than in women (4.72 vs 1.75%, p=0.06), and an increase with age (p=0,07), without statistical significance. Two positive samples for anti-HEV IgG were also IgM positive (2/19, 10.53%). RNA-HEV was detected in 1/547 (0.18%) samples, which corresponded to a 37-year-old male donor, without liver signs or symptoms or serological evidence of infection.
The resulted seroprevalences were similar to those previously described in the general population, reporting the first molecular finding in blood donors from Argentina. The local molecular prevalence is within the range described (0.012% to 0.6%) in blood donors from other non-endemic countries, in which immunocompetent RNA-HEV positive donors without serological evidence of infection were identified, highlighting: 1) the existence of the potential risk of transfusion transmission, particularly important for immunosuppressed patients; 2) the detection of HEV-RNA as the best option for screening in blood banks, although this would imply a high cost (thus pooling could be an appropriate option for HEV screening); and 3) the importance of continue HEV hemovigilance.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2021 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/35087 |
| work_keys_str_mv |
AT dicolag studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT pisanomb studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT blancos studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT fantilliac studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT martinezwassafmg studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT carrizolh studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT reve studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT gallegosv studyofthehepatitisevirusinblooddonorsfromcordobaserologicalandmolecularprevalence AT dicolag estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT pisanomb estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT blancos estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT fantilliac estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT martinezwassafmg estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT carrizolh estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT reve estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT gallegosv estudiodelvirusdelahepatitiseendonantesdesangredecordobaprevalenciaserologicaymolecular AT dicolag a AT pisanomb a AT blancos a AT fantilliac a AT martinezwassafmg a AT carrizolh a AT reve a AT gallegosv a |
| first_indexed |
2024-09-03T21:03:10Z |
| last_indexed |
2024-09-03T21:03:10Z |
| _version_ |
1809210294133587968 |
| spelling |
I10-R327-article-350872024-04-15T16:19:09Z Study of the hepatitis E virus in blood donors from Córdoba: serological and molecular prevalence Estudio del virus de la hepatitis E en donantes de sangre de Córdoba: prevalencia serológica y molecular A Di Cola, G Pisano , MB Blanco , S Fantilli, AC Martinez Wassaf , MG Carrizo , LH Ré , VE Gallego , SV HEV blood bank blood donors Córdoba HEV banco de sangre donantes de sangre Córdoba . Abstract: Hepatitis E virus (HEV), which causes acute hepatitis, can progress to chronicity in immunosuppressed patients. Transfusion transmission has been reported, being asymptomatic carriers a virus reservoir and a potential threat to transfusion safety. In Argentina, HEV is not tested in blood banks and its control is a matter of debate. Our objective was to determine HEV serological and molecular prevalence in blood donors from Córdoba. Five hundred and forty-seven plasma samples from blood donors (229 women, 318 men; median age: 35 years), obtained between February and May 2016 (n = 147), 2019 (n = 200), and 2020 (n = 200) were analyzed. IgG and IgM anti-HEV detection were performed by ELISA, and RNA detection was carried out by real-time RT-PCR and nested-PCR. Statistical analyzes were performed using R3.6.3 (statistical significance of p <0.05). The global prevalence of anti-HEV IgG was 3.7% (19/547), being similar in all years: 2.05% in 2016 (3/147), 3.50% in 2019 (7/200) and 4.50% in 2020 (9/200) (p=0,47). A greater trend in HEV seroprevalence was observed in men than in women (4.72 vs 1.75%, p=0.06), and an increase with age (p=0,07), without statistical significance. Two positive samples for anti-HEV IgG were also IgM positive (2/19, 10.53%). RNA-HEV was detected in 1/547 (0.18%) samples, which corresponded to a 37-year-old male donor, without liver signs or symptoms or serological evidence of infection. The resulted seroprevalences were similar to those previously described in the general population, reporting the first molecular finding in blood donors from Argentina. The local molecular prevalence is within the range described (0.012% to 0.6%) in blood donors from other non-endemic countries, in which immunocompetent RNA-HEV positive donors without serological evidence of infection were identified, highlighting: 1) the existence of the potential risk of transfusion transmission, particularly important for immunosuppressed patients; 2) the detection of HEV-RNA as the best option for screening in blood banks, although this would imply a high cost (thus pooling could be an appropriate option for HEV screening); and 3) the importance of continue HEV hemovigilance. Resumen: El virus de hepatitis E (HEV), causante de hepatitis aguda, puede progresar a hepatitis crónica en inmunosuprimidos. Se ha reportado transmisión por vía transfusional, siendo los portadores asintomáticos reservorios del virus y una potencial amenaza para la seguridad transfusional. En Argentina, el HEV no es testeado en bancos de sangre y su control es un tema de debate. Nuestro objetivo fue determinar la prevalencia serológica y molecular para HEV en donantes de sangre de Córdoba. Se estudiaron 547 muestras de plasma de donantes de sangre (229 mujeres, 318 hombres; mediana edad: 35 años), obtenidas entre febrero y mayo de 2016 (n=147), 2019 (n=200) y 2020 (n=200). Se realizó detección de IgG e IgM anti-HEV por ELISA, y de RNA mediante RT-PCR en tiempo real y nested-PCR. Se realizaron análisis estadísticos utilizando R3.6.3 (significancias estadísticas: p <0.05). La prevalencia global de IgG anti-HEV fue 3,47% (19/547) resultando similar en todos los años: 2,05% en 2016 (3/147), 3,50% en 2019 (7/200) y 4,50% en 2020 (9/200) (p=0,47). Se observó una tendencia mayor en hombres que en mujeres (4,72 vs 1,75%, p=0,06), y un aumento con la edad (p=0,07), sin significancia estadística. Dos muestras positivas para IgG anti-HEV resultaron IgM positivas (2/19, 10,53%). Se detectó RNA-HEV en 1/547 (0,18%) muestras, la cual correspondió a un donante masculino de 37 años, sin signos ni síntomas hepáticos ni evidencia serológica de infección. Las seroprevalencias obtenidas fueron similares a las descriptas previamente en población general, reportando el primer hallazgo molecular en donantes de sangre de Argentina. La prevalencia molecular local se encuentra dentro del rango descripto (0,012% a 0,6%) en donantes de sangre de otros países no endémicos, en los que se identificaron donantes inmunocompetentes RNA-HEV positivos sin evidencia serológica de infección, destacando: 1) la existencia del potencial riesgo de transmisión transfusional, particularmente importante para inmunosuprimidos; 2) la detección de RNA-HEV como la mejor opción para el screening en bancos de sangre, aunque esto implicaría un elevado costo, por lo que el agrupamiento en pools podría ser una opción apropiada para el tamizaje de HEV; y 3) la importancia de continuar la hemovigilancia de HEV. . Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-10-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto texto https://revistas.unc.edu.ar/index.php/med/article/view/35087 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. Suplemento (2021): Suplemento JIC XXII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. Suplemento (2021): Suplemento JIC XXII Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. Suplemento (2021): Suplemento JIC XXII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |